Tonix Pharmaceuticals initiated with a Buy at B. Riley FBR. B. Riley FBR analyst David Buck started Tonix Pharmaceuticals with a Buy rating and $8 price target. The analyst sees an attractive risk/reward ahead of a potential near-term catalyst for the company’s treatment of post-traumatic stress disorder.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.